US Stock Market Update | Redhill Biopharma surges 18% as opaganib shows potential for obesity-related diseases
I'm PortAI, I can summarize articles.
Redhill Biopharma announced positive results from multiple in vivo studies. These studies support the potential clinical applications of opaganib in the prevention and treatment of type 2 diabetes and other obesity-related diseases. As of the time of writing, Redhill surged 17.89% in early trading to $0.342. The research results demonstrate the benefits of opaganib therapy in inhibiting weight gain, reduced glucose tolerance, and fat deposition induced by HFD (high-fat diet). Furthermore, in HFD models already obese, opaganib therapy can slow weight gain and restore glucose tolerance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments